According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Pegargiminase (ADI-PEG 20) is a potential first-in-class targeted cancer therapy in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma (HCC ...

David M. Dudzinski: A 59-year-old man with a history of obesity, dyslipidemia, and hypertension was evaluated in the oncology clinic of this hospital because of hepatocellular carcinoma.

Yarchoan and his colleagues previously conducted the first clinical trials of immunotherapy before surgery for hepatocellular carcinoma ... is that this form is a late stage of tertiary lymphoid ...

China has unveiled the results of the world’s first advanced clinical trials of a cancer therapy based on a modified virus that can trigger a “tumour meltdown” in terminal-stage patients ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission (EC) to treat hepatocellular carcinoma ... and was supported by results ...

Tempest ended the year with $30.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023. The decrease was primarily due to cash used in operating activities, offset by ...

First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT ...